Antitumor activity in evaluable patients
| Characteristic . | Total (N = 221) . |
|---|---|
| Best overall response by central review, n (%) | |
| CR | 22 (10.0) |
| CRu | 8 (3.6) |
| PR | 60 (27.1) |
| Stable disease | 38 (17.2) |
| PD | 64 (29.0) |
| Not evaluable | 2 (0.9) |
| Not available | 9 (4.1) |
| Unknown (missing or no response assessment) | 18 (8.1) |
| ORR (CR + CRu + PR) by central review, n (%) | 90 (40.7); (95% CI, 34.2-47.5) |
| DoR, median (95% CI), mo | 9.1 (7.4-10.8) |
| PFS, median (95% CI), mo | 4.6 (3.2-5.6) |
| OS, median (95% CI), mo | 16.3 (13.1-22.6) |
| Kaplan-Meier OS estimates at 12 mo (95% CI) | 0.58 (0.51-0.64) |
| Kaplan-Meier OS estimates at 24 mo (95% CI) | 0.39 (0.32-0.46) |
| Characteristic . | Total (N = 221) . |
|---|---|
| Best overall response by central review, n (%) | |
| CR | 22 (10.0) |
| CRu | 8 (3.6) |
| PR | 60 (27.1) |
| Stable disease | 38 (17.2) |
| PD | 64 (29.0) |
| Not evaluable | 2 (0.9) |
| Not available | 9 (4.1) |
| Unknown (missing or no response assessment) | 18 (8.1) |
| ORR (CR + CRu + PR) by central review, n (%) | 90 (40.7); (95% CI, 34.2-47.5) |
| DoR, median (95% CI), mo | 9.1 (7.4-10.8) |
| PFS, median (95% CI), mo | 4.6 (3.2-5.6) |
| OS, median (95% CI), mo | 16.3 (13.1-22.6) |
| Kaplan-Meier OS estimates at 12 mo (95% CI) | 0.58 (0.51-0.64) |
| Kaplan-Meier OS estimates at 24 mo (95% CI) | 0.39 (0.32-0.46) |